Seagen highlights tukysa® (tucatinib) data in breast cancer at virtual 2020 san antonio breast cancer symposium

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) today announced the presentation of new data from tukysa (tucatinib), its her2-positive metastatic breast cancer therapy, at the san antonio breast cancer symposium (sabcs) virtual symposium, taking place december 8-11, 2020. nine abstracts – including two spotlight posters – highlight the company's commitment to addressing unmet needs in breast cancer. “following this year's fda approval of tukysa, we continue to broadly study if more
SGEN Ratings Summary
SGEN Quant Ranking